Vaccitech to Present an Update on Its Chronic HBV Infection Immunotherapeutic Program at The World Vaccine Congress Europe
13. Oktober 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech to Present at Upcoming September Investor conferences
09. September 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
12. August 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the second quarter, ended June 30, 2021, and provided an overview of...
Vaccitech to Present at the William Blair Biotech Focus Conference 2021
08. Juli 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, July 08, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Reports First Quarter 2021 Financial Results and Recent Corporate Developments
14. Juni 2021 17:49 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, June 14, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech to Present at the Jefferies Virtual Healthcare Conference
01. Juni 2021 08:00 ET
|
Vaccitech Limited
OXFORD, United Kingdom, June 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Announces Closing of $110.5 Million Initial Public Offering
04. Mai 2021 17:07 ET
|
Vaccitech Limited
OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics...
Vaccitech Announces Pricing of Initial Public Offering
29. April 2021 18:49 ET
|
Vaccitech Limited
OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
22. März 2021 04:00 ET
|
Vaccitech Limited
OXFORD, United Kingdom, March 22, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd (“Vaccitech”), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
18. März 2021 03:00 ET
|
Vaccitech Limited
OXFORD, United Kingdom, March 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines...